

ASX Announcement

Race Investor Information Sessions

8 August 2023 – Race Oncology Limited (“Race”) is pleased to invite shareholders and potential investors to attend a special investor Q&A session and / or an in person briefing in Sydney, Perth or Melbourne.

The online Q&A session will allow shareholders and potential investors the opportunity to ask questions in relation to Race’s strategic update (ASX Announcement: 8 August 2023).

The in-person briefing sessions will be attended by Race’s CEO & Managing Director, Damian Clarke-Bruce and Chief Medical Officer, Dr Michelle Rashford, who will present the Company’s strategic update. Each formal presentation will be followed by a Q&A session.

Shareholder sessions – please register to attend:

Online Q&A session:	Wednesday, 9 August 2023, 7.30pm Any shareholders / potential investors wishing to attend are required to register ahead of time via the following link: https://us02web.zoom.us/webinar/register/WN_y2egSTBaS2SozEEAQ4D5bQ After registering, you will receive a confirmation email with details explaining how to join the webinar.
In-person briefings Shareholders and potential investors wishing to attend one of the in-person events outlined above must RSVP by COB Thursday, 10 August 2023 by contacting the person below and noting your name, email, contact number and which briefing session you are attending (Sydney, Perth or Melbourne): Phillipa Thorn phillipa.thorn@irdepartment.com.au +61 404 839 848	
Sydney:	Friday, 11 August 2023, 12pm Gallery Room, State Library of NSW 1 Shakespeare Place, Sydney Light lunch provided
Perth:	Tuesday, 15 August 2023, 12pm Subi Continental Cnr Rokeby and Roberts Road, Subiaco Light lunch provided
Melbourne:	Thursday, 17 August 2023, 6.30pm InvestorHub Level 16, 452 Flinders St, Melbourne Drinks and light refreshments provided

The Race team looks forward to welcoming all those shareholders and potential investors who are able to attend.

If you are unable to attend any of the in-person briefing sessions, you can access the video presentation here: <https://raceoncology.com/?p=5619>.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.

Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.

As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m⁶A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.

Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Damian Clarke-Bruce, CEO/MD on behalf of the
Race Board of Directors
damian.clarke-bruce@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au